Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Palomid 529 (P529) is an inhibitor of mammalian target of rapamycin complex (mTORC) formation.1 It is a derivative of a non-steroidal estrogen antagonist that has anti-angiogenic and anticancer activity but lacks estrogen receptor binding activity in estrogen binding assays in vitro. Palomid 529 inhibits VEGF-driven and bFGF-driven endothelial cell proliferation (IC50s = 20 and 30 nM, respectively) and reduces VEGF-A-driven phosphorylation of AktS473, an mTORC2 substrate. In vivo, palomid 529 inhibits retinal neovascularization in mice with oxygen-induced retinopathy, a commonly used assay for pathogenic angiogenesis, Ad-VEGF-A-driven angiogenesis, and phosphorylation of AktS473. Palomid 529 has anticancer effects in glioma cancer cells and xenografts via AktS473 signaling downtstream of mTORC.
WARNING This product is not for human or veterinary use.
1. Palomid 529, a novel small-